CAS No.
[873054-44-5 (Unlabeled)]
Storage Condition
Store at refrigerator (2-8°C) for long term storage
Application Notes
Useful research chemical for a range of applications
Purity by HPLC
Not less than 90%
Hazard Compound
No -Refer MSDS for accurate information
Ivacaftor-d4 is a drug product that is used as an analytical standard for HPLC, as well as in research and development of drugs.
Refund Policy
We are committed to offering products of the highest quality in order to meet the needs of our customers, and have elaborate systems in
place to ensure that material specifications, their certification and all handling and storage conditions are communicated at the time of
material handover.
We have invested in the highest quality packaging materials and use international logistics partners to service our customers. While all
possible precautions have been taken to deliver the required product(s), there may be some rare situations when our product does not
meet your requirements. Should that arise, please contact us with your concerns and we will endeavour to address them on a priority
basis. If there is no other option, we will either replace your product(s) or issue a refund or account credit, whichever you prefer.
If there is an issue with one or more of our products, our policy is that it must be reported to us within 45 days of your receiving shipment.
While we will always address product issues after the 45 day return window has passed, we cannot issue a refund or account credit. As
always, we appreciate your support.
Ivacaftor-d4 usage and description
Ivacaftor D4 is a deuterated form of Ivacaftor, a medication used in the treatment of cystic fibrosis. Cystic fibrosis is a genetic disorder that affects the respiratory, digestive, and reproductive systems. It is caused by mutations in the CFTR (cystic fibrosis transmembrane conductance regulator) gene, which codes for a protein that regulates the movement of salt and water in and out of cells.
Ivacaftor D4 works by targeting the CFTR protein and enhancing its function, which improves the movement of salt and water in and out of cells. This results in improved lung function and a reduction in the frequency and severity of respiratory infections in people with cystic fibrosis. Ivacaftor D4 is administered orally, and the dosage depends on the patient's age and weight.
Chemically, Ivacaftor D4 is a deuterated form of Ivacaftor, meaning that it contains deuterium, a stable isotope of hydrogen. This modification enhances the drug's metabolic stability, which increases its half-life and reduces the frequency of dosing. It also reduces the potential for drug interactions and improves the drug's safety profile.
Overall, Ivacaftor D4 is an important medication in the treatment of cystic fibrosis. Its targeted mechanism of action and chemical modifications make it an effective and safe therapy for patients with this debilitating condition.
